Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfIntangibleAssetsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2024-01-01
-Paragraph 118
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard
-URIDate 2024-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2024-01-01
-Paragraph 54
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The remaining amortisation period of individual intangible assets that are material to the entity’s financial statements. [Refer: Depreciation and amortisation expense]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 38
-IssueDate 2024-01-01
-Paragraph 122
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_b&doctype=Standard
-URIDate 2024-03-27

+ Details

Name:	ifrs-full_RemainingAmortisationPeriodOfIntangibleAssetsMaterialToEntity2019
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=tak_ProductRelatedIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=tak_MarketedProductsIntangibleAssetsOtherThanGoodwillMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_ImmunoglobulinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_TakhzyroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_AdvateAndAdynovateAdynoviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_AlunbrigMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_VyvanseElvanseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=tak_ResearchAndDevelopmentInProcessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=tak_TAK279Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Intangible Assets - Schedule of Intangible Assets Associated with Products (Details) - JPY (¥) ¥ in Millions	12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2023
Intangible assets associated with products
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 3,475,773	¥ 4,113,726	¥ 4,135,020
Marketed products
Disclosure of detailed information about intangible assets [line items]
Intangible assets	2,556,431	3,148,680	3,164,380
Marketed products \| Immunoglobulins
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 710,287	795,903
Remaining amortization period	10 years
Marketed products \| TAKHZYRO
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 496,676	562,434
Remaining amortization period	9 years
Marketed products \| ADVATE & ADYNOVATE/ADYNOVI
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 220,595	269,275
Remaining amortization period	5 years
Marketed products \| ALUNBRIG
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 163,329	212,376
Remaining amortization period	6 years
Marketed products \| VYVANSE/ELVANSE
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 95,566	223,589
Remaining amortization period	1 year
In-process R&D
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 919,342	965,045	¥ 970,640
In-process R&D \| Zasocitinib (TAK-279)
Disclosure of detailed information about intangible assets [line items]
Intangible assets	¥ 609,329	¥ 613,329